CellWell record HH-583552
Interferon-alpha and transfer factor in the treatment of multiple sclerosis: a double-blind, placebo-controlled trial. AUSTIMS Research Group
Journal of neurology, neurosurgery, and psychiatry ยท 1989
In plain language
In a three-year double-blind placebo-controlled trial of 182 multiple sclerosis patients, injected interferon-alpha or transfer factor did not slow disability progression versus placebo, and interferon-alpha caused more adverse reactions and withdrawals; funding not stated.
- Evidence
- Established
- Design
- Randomized controlled trial
Cite this record: https://thecellwell.org/studies/HH-583552
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.